Boehringer Ingelheim
 |
|
| Type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founded | Germany (1885) |
| Headquarters | Binger Str. 173, 55216 Ingelheim Germany |
| Key people | Andreas Barner, Chairman of the board Hubertus von Baumbach, board member Wolfram Carius, board member Engelbert Tjeenk Willink, board member |
| Products | Human Pharmaceuticals and Animal Health |
| Revenue |  €12.586 billion EUR (2010) |
| Operating income | €1.896 billion EUR (2010) |
| Net income | €888 million EUR (2010) |
| Employees | 42,224 (2010) |
| Website | http://www.boehringer-ingelheim.com |
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. The companies key assets of interest are: respiratory disease, cardiovascular disease, Parkinson's disease, HIV, thromboembolic disease and cerebrovascular disease. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.[1]
Contents |
[edit] Fields of activity
The business areas consist of Human Pharmaceuticals and Animal Health. In 2010, 42,224 employees were in 145 affiliated companies worldwide, research and development (R&D) facilities were in seven sites and 20 production plants in 13 countries. Boehringer Ingelheim's Pharma Chemicals business has pioneered the commercial production of monomers and biodegradable polymers for more than 20 years.
[edit] Collaborative research
In addition to internal research and development activities Boehringer Ingelheim is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[2][3] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[4]
[edit] Operational/development sites
The company's largest site and corporate headquarters is located in Ingelheim am Rhein near Mainz and Frankfurt, Germany. However, Boehringer Ingelheim is a globally-operating company, with 145 subsidiaries around the globe. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology[5] in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.
In December 2008, the Boehringer Ingelheim group of companies had 41,300 employees worldwide. Of these, about 30% worked in production, 39% in marketing and sales, and 16.5% in research and development. In 2005, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times' 100 Best Companies To Work For. In 2006 the Science magazine (US) listed Boehringer Ingelheim as second place for top employers in the biotechnology and pharmaceutical industries.[5]
In 2010, the Boehringer Ingelheim group of companies had 42,224 employees worldwide. Of these, 12,647 worked in production, 16,543 in marketing and sales, and 7,093 in research and development. In Germany, Brazil, the Netherlands, and the United Kingdom, Boehringer Ingelheim received recognition as one of the best employers for the year 2009. In 2009 the English newspaper ‘Sunday Times’ placed the company in the list ‘Best Places to Work’. The ‘Workforce Diversity Magazine’ and the ‘Careers & the disABLED Magazine’ placed Boehringer Ingelheim as “A Top 50 Employer, Reader’s Choice: 2009”.
[edit] Key product lines
Aggrenox, Antistax, Bisolvon, Buscopan, Buscapina, CircoFLEX, Dulcolax, Duramune, Flomax, Metacam, Micardis + Micardis Plus, Mirapex, Mucosolvan, Mucoangin, Mobic, Spiriva, Pharmaton, Pradaxa, Resomer, Vetmedin, Viramune, Zantac, Twynsta.
[edit] See also
[edit] Notes
- ^ "Boehringer Ingelheim Logo: Design and History". FamousLogos.us. http://www.famouslogos.us/boehringer-ingelheim-logo. Retrieved 2011-08-18.
- ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
- ^ "InnoMed PredTox Member Organizations". http://www.innomed-predtox.com/consortium/members/. Retrieved 2008-08-25.
- ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. http://imi.europa.eu/docs/calls01_en.zip. Retrieved 2008-08-25.[dead link]
- ^ Gwynne, Peter (October 20, 2006), "TOP EMPLOYER SURVEY: It All Starts with Science",Science. Retrieved August 26, 2007.
[edit] External links
- Boehringer Ingelheim Corporate website
- Boehringer Ingelheim Vetmedica United States Animal Health website
- Boehringer Ingelheim German website
- Boehringer Ingelheim USA website
- News-Centre (for journalists)
- Social Media at Boehringer Ingelheim
- CHC Products
- Boehringer Ingelheim Italia
- Boehringer Ingelheim Argentina
- Boehringer Ingelheim (Canada) Ltd.
- Boehringer Ingelheim Brazil
- Boehringer Ingelheim Spain
- Boehringer Ingelheim Mexico
- Site Buscopan Brazil
- Boehringer Ingelheim UK
- Boehringer Ingelheim Japan
